Pharmacy Technology

BURLINGTON, Mass. The drug market for Crohn's disease treatments will see moderate growth over the next decade, Decision Resources reported Wednesday.

The research firm projected that the market will increase a little more than 31%, from $3.2 billion in 2009 to $4.2 billion in 2019, in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Decision Resources said the the modest growth rate masks such market changes as new and emerging biologics, as well as generic competition.

CAMDEN, N.J. Campbell Soup Co.'s chief executive is retiring at the end of the company's fiscal year.

Doug Conant will step down from his role as president and CEO, a position he has held since 2001, on July 31, 2011, the company said Tuesday. Campbell's board of directors appointed EVP and COO Denise Morrison to lead the company at the beginning of fiscal 2012. Morrison also has been elected a director of the company as of Oct. 1.

PARK CITY, Utah A healthcare technology company that uses social media and self-management tools to help people with chronic illnesses is launching a mobile health technology designed to improve adherence.

KeyVive said that its Simplatype mHealth technology, a new SMS system, utilizes proprietary technology with existing cell phone carriers to provide an effective way for practitioners and patients to communicate, store conversations and integrate with electronic records, the company said.

PRINCETON, N.J. Condom producer Trojan is launching a new line of vibrators, the company said Tuesday.

Trojan announced the introduction of Trojan Vibrations, which it described as powerful but with soft textures. The first, Vibrating Tri-Phoria, will become available in retail pharmacies and mass merchandisers in 2011.

NEW YORK Pfizer has halted a late-stage trial of a drug therapy in men with prostate cancer, the drug maker said.

Pfizer announced the discontinuation of “SUN 1120,” a phase-3 trial of Sutent (sunitinib malate) combined with the generic drug prednisone in men with advanced castration-resistant prostate cancer that had progressed despite chemotherapy. An analysis of data from the trial found that the men were not more likely to improve overall survival when taking the two drugs together than when they took prednisone alone.